Jiangsu Key Laboratory for Supramolecular Medicinal Materials and Applications, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China.
J Agric Food Chem. 2011 Sep 14;59(17):9280-9. doi: 10.1021/jf202135j. Epub 2011 Aug 8.
The overall goal of this paper was to develop poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) of curcumin (CUR), named CUR-PLGA-NPs, and to study the effect and mechanisms enhancing the oral bioavailability of CUR. CUR-PLGA-NPs were prepared according to a solid-in-oil-in-water (s/o/w) solvent evaporation method and exhibited a smooth and spherical shape with diameters of about 200 nm. Characterization of CUR-PLGA-NPs showed CUR was successfully encapsulated on the PLGA polymer. The entrapment efficiency and loading rate of CUR were 91.96 and 5.75%, respectively. CUR-PLGA-NPs showed about 640-fold in water solubility relative to that of n-CUR. A sustained CUR release to a total of approximately 77% was discovered from CUR-PLGA-NPs in artificial intestinal juice, but only about 48% in artificial gastric juice. After oral administration of CUR-PLGA-NPs, the relative bioavailability was 5.6-fold and had a longer half-life compared with that of native curcumin. The results showed that the effect in improving oral bioavailability of CUR may be associated with improved water solubility, higher release rate in the intestinal juice, enhanced absorption by improved permeability, inhibition of P-glycoprotein (P-gp)-mediated efflux, and increased residence time in the intestinal cavity. Thus, encapsulating hydrophobic drugs on PLGA polymer is a promising method for sustained and controlled drug delivery with improved bioavailability of Biopharmaceutics Classification System (BCS) class IV, such as CUR.
本文的总体目标是开发姜黄素(CUR)的聚(乳酸-共-乙醇酸)纳米粒子(PLGA-NPs),并命名为 CUR-PLGA-NPs,以研究提高 CUR 口服生物利用度的作用和机制。CUR-PLGA-NPs 是根据固-油-水(s/o/w)溶剂蒸发法制备的,呈光滑球形,直径约为 200nm。CUR-PLGA-NPs 的特性表明 CUR 已成功包封在 PLGA 聚合物上。CUR 的包封效率和载药量分别为 91.96%和 5.75%。与游离 CUR 相比,CUR-PLGA-NPs 在水中的溶解度约提高了 640 倍。在人工肠液中,CUR-PLGA-NPs 中约有 77%的 CUR 可实现持续释放,但在人工胃液中仅约 48%。与天然姜黄素相比,CUR-PLGA-NPs 口服给药后的相对生物利用度提高了 5.6 倍,半衰期更长。结果表明,提高 CUR 口服生物利用度的效果可能与改善水溶性、提高肠液中的释放率、通过增加通透性来增强吸收、抑制 P-糖蛋白(P-gp)介导的外排以及增加在肠腔中的停留时间有关。因此,将疏水性药物包封在 PLGA 聚合物上是一种很有前途的方法,可以持续控制药物释放,提高生物利用度,改善生物药剂学分类系统(BCS)IV 类药物(如 CUR)的生物利用度。